S

Starton Holdings, Inc.

STAFiled

Starton Holdings, Inc. · Nasdaq Capital Market · latest filing 2026-07-13

Report source
One-minute decisionBASIC RESEARCHSource completeness · 86%

IPO research

Starton Holdings is a clinical-stage oncology biotechnology company proposing a 5.0 million-share IPO at an estimated $5.00–$7.00 per share. The filing presents substantial development, financing, going-concern, control and dilution risks; the registration statement remains preliminary and is not yet effective.

Starton Holdings has filed Amendment No. 5 to an S-1 registration statement for a proposed Nasdaq IPO of 5,000,000 common shares under STA.

Where does the money go?Awaiting verificationS-1/A · 2026-07-13
Ownership and votingAwaiting verified holder data— economic · — voting
Next disclosed checkpointSEC effectiveness, final pricing, Nasdaq listing and offering closing; no effective date or delivery date is supplied.S-1/A · 2026-07-13

Capital destination

Awaiting verification

S-1/A · 2026-07-13

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
Next checkSEC effectiveness, final pricing, Nasdaq listing and offering closing; no effective date or delivery date is supplied.
Latest filing2026-07-13

Capital destination

Awaiting verification

S-1/A · 2026-07-13

Share-type percentages are not net-proceeds percentages. Amounts retain their stated gross/net basis; do not add unlike bases.

Check the source · S-1/A ↗
BOOKRUNNERS / LEAD UNDERWRITERSBookrunners / lead underwriters
NOT YET DISCLOSED

Names not yet published

Fully diluted valuation bridge

StatusReference
Awaiting verificationSource ↗

Basic-price scenario

A verified single offer price and basic post-offer share count are required. This is a data gap, not a paid lock.

Check the source · S-1/A ↗

Holder data awaits verification

The evidence identifies concentrated ownership risk. Current disclosed ownership for executive officers and directors as a group is 8,430,434 shares, or 23.71% before the offering and 20.34% on the stated post-offering basis. Special voting shares and exchangeable shares create additional control complexity. · 2026-07-13

The evidence identifies concentrated ownership risk. Current disclosed ownership for executive officers and directors as a group is 8,430,434 shares, or 23.71% before the offering and 20.34% on the stated post-offering basis. Special voting shares and exchangeable shares create additional control complexity.

One disclosed holder; not a complete ownership distribution.Check the source · S-1/A ↗

Conditional lock-up timeline

StatusReference
Awaiting verificationSource ↗

Financial quality and runway

StatusReference
Awaiting verificationSource ↗

Latest filing update

Loading saved filing update…

SEC filing history

Loading filing history…

Risk 1

The company is clinical-stage, has no approved commercial products and has incurred net losses since inception.

Potential impact
Awaiting verification
Monitor
SEC effectiveness, final pricing, Nasdaq listing and offering closing; no effective date or delivery date is supplied.
SEC EDGAR

S-1/A

2026-07-13

Open SEC filing ↗